Gritstone Bio Other Long-Term Assets 2017-2024 | GRTSQ
Gritstone Bio other long-term assets from 2017 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Gritstone Bio Annual Other Long-Term Assets
(Millions of US $) |
| 2023 |
$6 |
| 2022 |
$15 |
| 2021 |
$8 |
| 2020 |
$3 |
| 2019 |
$3 |
| 2018 |
$2 |
| 2017 |
$2 |
| 2016 |
$1 |
Gritstone Bio Quarterly Other Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$5 |
| 2024-03-31 |
$6 |
| 2023-12-31 |
$6 |
| 2023-09-30 |
$7 |
| 2023-06-30 |
$8 |
| 2023-03-31 |
$19 |
| 2022-12-31 |
$15 |
| 2022-09-30 |
$11 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$7 |
| 2021-12-31 |
$8 |
| 2021-09-30 |
$8 |
| 2021-06-30 |
$3 |
| 2021-03-31 |
$3 |
| 2020-12-31 |
$3 |
| 2020-09-30 |
$3 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$3 |
| 2019-09-30 |
$3 |
| 2019-06-30 |
$3 |
| 2019-03-31 |
$3 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$2 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2016-12-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
